NovaBridge Biosciences officer reports equity holdings

NovaBridge Biosciences executive Wu Joanna Xuqiong has reported her current equity holdings in the company.

Rhea-AI Filing Summary

NovaBridge Biosciences executive Wu Joanna Xuqiong has reported her current equity holdings in the company. She directly holds options over 46,875 Ordinary Shares under a 2026 employee share option at an exercise price of $3.3100 per share, expiring on February 1, 2036. She also holds 24,169 Restricted Share Units that each represent a contingent right to receive one American Depositary Share, vesting over four years from a February 1, 2026 grant date. In addition, she owns 1,150 Ordinary Shares directly and 4,600 Ordinary Shares indirectly through her spouse. The ratios in the footnotes state that each 10 ADSs represent 23 Ordinary Shares, with certain reported positions represented by 500 and 2,000 ADSs.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Wu Joanna Xuqiong

Role See Remarks

Type	Security	Shares	Price	Value
holding	2026 Employee Share Option (right to buy)	--	--	--
holding	Restricted Share Units	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: 2026 Employee Share Option (right to buy) — 46,875 contracts (Direct); Restricted Share Units — 24,169 contracts (Direct); Ordinary Shares — 1,150 shares (Direct); Ordinary Shares — 4,600 shares (Indirect, Spouse)

Footnotes (6)

1. F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. F2. Reported securities are represented by 500 ADSs.
3. F3. Reported securities are represented by 2,000 ADSs.
4. F4. Number of underlying securities and exercise price expressed in terms of ADSs.
5. F5. The option was granted on February 1, 2026. The option vests and becomes exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the first day of each third month.
6. F6. On February 1, 2026, the Reporting Person was granted 24,169 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the first day of each third month.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does NovaBridge Biosciences (NBP) Form 3 show for Wu Joanna Xuqiong?

The Form 3 shows Wu Joanna Xuqiong’s existing equity stake, including options, restricted share units, and Ordinary Shares. It establishes her starting ownership position as an officer, rather than reporting new market purchases or sales.

How many options does Wu Joanna Xuqiong hold in NovaBridge Biosciences (NBP)?

She holds a 2026 employee share option over 46,875 Ordinary Shares at an exercise price of $3.3100 per share. These options expire on February 1, 2036 and vest over four years from the grant date, according to the footnotes.

What restricted share units are reported for Wu Joanna Xuqiong at NovaBridge Biosciences (NBP)?

She was granted 24,169 restricted share units on February 1, 2026. Each RSU represents a contingent right to receive one American Depositary Share, vesting over four years with one-fourth after one year and the rest quarterly thereafter.

Does the NovaBridge Biosciences (NBP) Form 3 show any insider buying or selling?

The Form 3 lists holdings only and does not show any insider purchases or sales. All entries are classified as holdings, meaning it records existing positions rather than new market transactions in NovaBridge Biosciences shares or ADSs.

What direct Ordinary Share holdings does Wu Joanna Xuqiong report in NovaBridge Biosciences (NBP)?

She reports direct ownership of 1,150 Ordinary Shares. This is separate from her derivative positions, such as employee share options and restricted share units, and from any shares attributed indirectly through her spouse’s holdings.

How are indirect holdings reported for Wu Joanna Xuqiong in NovaBridge Biosciences (NBP)?

The filing shows 4,600 Ordinary Shares held indirectly through her spouse. These are classified as indirect ownership, distinct from her direct share, option, and RSU positions disclosed in the same Form 3 overview.

What ADS to Ordinary Share ratio is disclosed for NovaBridge Biosciences (NBP)?

The footnotes state that each 10 American Depositary Shares represent 23 Ordinary Shares of NovaBridge Biosciences. Certain reported securities are described as being represented by 500 ADSs and 2,000 ADSs under this ratio framework.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:39 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wu Joanna Xuqiong

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	1,150(2)	D
Ordinary Shares(1)	4,600(3)	I	Spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2026 Employee Share Option (right to buy)	(5)	02/01/2036	Ordinary Shares(1)	46,875(4)	$3.31(4)	D
Restricted Share Units	(6)	(6)	Ordinary Shares(1)	24,169(4)	(6)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 500 ADSs.

3. Reported securities are represented by 2,000 ADSs.

4. Number of underlying securities and exercise price expressed in terms of ADSs.

5. The option was granted on February 1, 2026. The option vests and becomes exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the first day of each third month.

6. On February 1, 2026, the Reporting Person was granted 24,169 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the first day of each third month.

Remarks:

Senior Vice President, Head of Operations, General Counsel (US) Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact_	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)